Medical Oncology Department, Eugène Marquis Comprehensive Cancer Center, 35043 Rennes, France.
Hum Pathol. 2012 Nov;43(11):1982-90. doi: 10.1016/j.humpath.2012.01.023. Epub 2012 May 22.
Angiogenesis in clear cell renal cell carcinoma has received recent focus with the development of antiangiogenic therapies. Although tumor progression is known to be correlated with intratumoral and plasma levels of vascular endothelial growth factor-A, the role of tumor induced-angiogenesis remains unclear in these tumors. We analyzed the vascular network in a cohort of 73 clear cell renal cell carcinoma cases using endothelial immunostaining. We studied protein expression of vascular endothelial growth factor, Von Hippel Lindau, and carbonic anhydrase IX by immunohistochemistry, Von Hippel Lindau gene alteration by sequencing, deletion- and methylation-specific Multiplex Ligation-dependent Probe Amplification, and gene expression by pangenomic microarray and quantitative polymerase chain reaction in a subcohort of 39 clear cell renal cell carcinoma cases. We described 2 distinct angiogenic phenotypes in comparison with the normal kidney vasculature: low and high angiogenic phenotypes. The low angiogenic phenotype was associated with more aggressive prognostic factors such as T3 to T4 (62% versus 31%, P=.002), N+ (29% versus 3% P=.004), M+ (53% versus 21%, P=.004) stages, Fuhrman grade (grade 3-4: 91% versus 36%, P<.001), and intratumoral vascular endothelial growth factor expression (74% versus 28%, P<.001); was less associated with Von Hippel Lindau inactivation (56% versus 80%, P=.03); and was a predictor of poor prognosis in terms of progression-free, cancer-specific, and overall survival (log-rank test, P=.002, P=.011, and P=.035, respectively). The low angiogenic phenotype was also associated with a relative down-regulation of gene expression (platelet-derived growth factor D, N-acetyl transferase 8, and N-acetyl transferase 8 B). In conclusion, the histologic and molecular distinction between these 2 angiogenic phenotypes could help to better understand the biologic behavior of clear cell renal cell carcinoma angiogenesis and could be analyzed in a prospective study of the effects of antiangiogenic drugs.
在抗血管生成治疗发展的背景下,肾透明细胞癌中的血管生成最近受到了关注。尽管肿瘤进展与肿瘤内和血浆血管内皮生长因子-A 水平相关,但这些肿瘤中肿瘤诱导的血管生成的作用仍不清楚。我们使用内皮免疫染色分析了 73 例肾透明细胞癌病例的血管网络。我们通过免疫组化研究了血管内皮生长因子、VHL 和碳酸酐酶 IX 的蛋白表达,通过测序研究了 VHL 基因改变,通过删除和甲基化特异性多重连接依赖性探针扩增研究了基因缺失和甲基化,并通过基因芯片和定量聚合酶链反应研究了 39 例肾透明细胞癌病例的基因表达。与正常肾脏血管相比,我们描述了 2 种不同的血管生成表型:低血管生成表型和高血管生成表型。低血管生成表型与更具侵袭性的预后因素相关,如 T3 至 T4(62%与 31%,P=0.002)、N+(29%与 3%,P=0.004)、M+(53%与 21%,P=0.004)期、Fuhrman 分级(3-4 级:91%与 36%,P<.001)和肿瘤内血管内皮生长因子表达(74%与 28%,P<.001);与 VHL 失活的相关性较小(56%与 80%,P=0.03);并且是无进展生存、癌症特异性生存和总生存的不良预后预测因子(对数秩检验,P=0.002、P=0.011 和 P=0.035)。低血管生成表型还与基因表达的相对下调相关(血小板衍生生长因子 D、N-乙酰基转移酶 8 和 N-乙酰基转移酶 8B)。总之,这两种血管生成表型之间的组织学和分子差异有助于更好地理解肾透明细胞癌血管生成的生物学行为,并且可以在抗血管生成药物效果的前瞻性研究中进行分析。